Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT06604897 · ClinicalTrials.gov registry record
Effectiveness of Entresto (Sacubitril/Valsartan) in Japanese Patients With Hypertension
A clinical trial of Essential Hypertension, sponsored by Novartis.
- Active
- Registry status
- 1,405
- Enrollment target
- 1
- Study location
NCT06604897: Active study of Essential Hypertension, sponsored by Novartis.
NCT06604897 is a study of Essential Hypertension that is active but no longer recruiting, run by Novartis. The registered enrollment target is 1,405 participants, above the 628-participant average among 8 other Essential Hypertension trials with a reported enrollment target (124% higher). The trial reports 1 study location across 1 state. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT06604897, a study of Essential Hypertension, is active but no longer recruiting, sponsored by Novartis.
- ACTIVE NOT RECRUITING
- Registry status
- 1,405 participants
- Enrollment target
- 1
- Study location
Study Summary
This study is a non-interventional, secondary use of data, retrospective, cohort study, and the data to be extracted in this study will be used as secondary use of collected patient information in the database (Japan Medical Data Survey \[JAMDAS\]) owned by M3 Inc. JAMDAS is a database that aggregates medical information and is constructed mainly from electronic medical record information of general practices, allowing real-time extraction of information entered in medical records, such as prescription status including drug switching and continuation, laboratory values, clinical evaluation scores, and comorbidities, etc.
Primary Outcome
The Japanese Society of Hypertension Guidelines for the Management of Hypertension (JSH 2019) will be used to establish systolic and diastolic blood pressure goals.
Conditions Studied
Study Locations (1)
New Jersey
- Novartis - East Hanover
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 1,405 participants |
| Start Date | 2023-01-31 |
| Est. Completion | 2025-03-31 |
What the registry record for NCT06604897 still lists
NCT06604897 is an observational study that tracks outcomes without assigning an intervention. Its 1,405 participants enrollment target places it among the larger protocols in the corpus, above the 628-participant average among 8 other Essential Hypertension trials with a reported enrollment target (124% higher).
The record links to 1 condition, with Essential Hypertension appearing as the primary indexed condition, and to 0 interventions.
NCT06604897 reports a single indexed study location in New Jersey.
Frequently Asked Questions
What is clinical trial NCT06604897 about?
NCT06604897 is a clinical study titled "Effectiveness of Entresto (Sacubitril/Valsartan) in Japanese Patients With Hypertension". This study is a non-interventional, secondary use of data, retrospective, cohort study, and the data to be extracted in this study will be used as secondary use of collected patient information in the database (Japan Medical Data Survey \[JAMDAS\]) owned by M3 Inc. JAMDAS is a database that aggregat...
What is the current status of trial NCT06604897?
This trial is currently active not recruiting. The enrollment target is 1,405 participants. The study started on 2023-01-31. Estimated completion is 2025-03-31.
What conditions does trial NCT06604897 study?
This clinical trial studies the following conditions: Essential Hypertension.
Who is sponsoring clinical trial NCT06604897?
This trial is sponsored by Novartis, which has 265 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT06604897 being conducted?
This trial has 1 study location across New Jersey. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Essential Hypertension
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
Where NCT06604897's enrollment target sits among peer trials
1,405 2nd of 8 the highest of 8 other Essential Hypertension trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Essential Hypertension trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
-
Childhood-Onset Essential Hypertension Natural History Study
RECRUITING
-
Uric Acid in Essential Hypertension in Children
COMPLETED · Phase 2
-
Hypertension: Prediction of Biofeedback Success
COMPLETED · Phase 1
-
Bioequivalency Study of Perindopril Erbumine 8 mg Tablet Under Fasted Conditions
COMPLETED · NA
-
A Long Term Safety Study to Test the Combination of Aliskiren/ Amlodipine / Hydrochlorothiazide in Participants With Essential Hypertension
COMPLETED · Phase 3
-
Efficacy and Safety of Once Daily Dosing of Aliskiren (300 mg (qd) Once a Day) to Twice Daily Dosing of Aliskiren (150 mg (Bid) Twice a Day) in Treating Moderate Hypertension.
COMPLETED · Phase 4
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT05992935 · 1,405 participants · Phase 1
Study to Evaluate the Safety, Reactogenicity, and Immunogenicity of mRNA-1403 and mRNA-1405 to Prevent Norovirus Acute Gastroenteritis in Healthy Adults 18 to 80 Years of Age
- NCT05444582 · 1,404 participants · Phase 4
Levonorgestrel 52 mg IUD for Emergency Contraception and Same-Day Start
- NCT05890404 · 1,410 participants · NA
SGM Evidenced-Based Mental Healthcare Implementation
- NCT07042451 · 1,410 participants · NA
An Evaluation of the Pink Cloud Application in Post- Treatment Substance Use Disorder Support
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI